Navigation Links
Cardiovascular issues up mortality rates in patients with advanced fibrosis
Date:4/10/2013

New research reveals that advanced fibrosis is a significant predictor of mortality in patients with nonalcoholic fatty liver disease (NAFLD), largely brought about by cardiovascular causes. NAFLD alone was not associated with increased mortality according to findings published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

With super-sized portions, sugary soft drinks and physical inactivity, obesity is on the rise and showing no sign of slowing. Studies report that the prevalence of obesity has doubled in the U.S. over the past 25 years. As obesity rates have soared, so has the incidence of NAFLD, making it the most prevalent liver disease in the U.S.

NAFLD is a chronic form of liver disease that includes such conditions as steatosis without fibrosis, nonalcoholic steatohepatitis (NASH) with fibrosis, and cirrhosis. Fibrosis is the progressive scarring of the liver with stages ranging from zero to four (cirrhosis). Medical evidence has found that patients with simple steatosis have a better prognosis than those with NASH, which could progress to end-stage liver disease.

Lead investigator Dr. W. Kim Ray from the Mayo Clinic in Rochester, Minn. explains, "The effect of NAFLD on public health is not well understood. Large, population-based studies, which can provide insight into disease activity, present some difficulty given that liver biopsy is required to confirm NAFLD."

To investigate the long-term impact of NAFLD on mortality, the team used data from the National Health and Nutrition Examination Survey (NHANES)a survey by the National Center for Health Statistics in conjunction with the Centers for Disease Control and Prevention (CDC) that was conducted from 1988 to 1994 with mortality follow-up through 2006. NAFLD was diagnosed by ultrasound and severity of fibrosis was measured by non-invasive fibrosis markers such as the NAFLD fibrosis score (NFS).

Findings indicate that of the 11,154 participants, 34% had NAFLD, with 72% of these patients having a NFS that indicated lack of significant fibrosis (NFS less than -1.455) and 3% with advanced fibrosis (NFS greater than 0.676). NAFLD was not associated with higher mortality risk after a median of 15 years of follow-up.

Further analysis shows that mortality increases as fibrosis advances. In fact, patients likely to progress to advanced fibrosis had a 69% increase in mortality compared to those without fibrosis. Higher mortality in those with advanced fibrosis was largely due to cardiovascular causes, more than expected from conditions common in patients with NAFLD such as high blood pressure or high levels of cholesterol. "Our findings confirm that NAFLD patients without advanced fibrosis do not have higher mortality risk," concludes Dr. Kim. "Careful monitoring of disease progression in patients with NAFLD and fibrosis, along with interventions that reduce cardiovascular risk factors are warranted."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Record Attendance at the Accreditation for Cardiovascular Excellence, ACE, Exhibit Booth at ACC.13
2. ACE, the Accreditation for Cardiovascular Excellence, Cited as Effective Program for Restoring Hospital Reputation
3. Delgado Protocol Announces Adrenal DMG, An Amazing New Supplement Designed to Support the Immune, Circulatory and Cardiovascular Systems
4. Los Angeles Periodontist, Dr. Markzar, is Now Informing Patients about the Possible Connection between Gum Disease and Cardiovascular Disease
5. Tooth loss associated with cardiovascular risk factors in patients with chronic heart disease
6. ViVitro Labs Adds Real-Time Wear Tester to Their Line of Cardiovascular Device Testing Equipment
7. Cardiovascular risk may remain for treated Cushings disease patients
8. Mainz University Medical Center receives further DFG funding for cardiovascular research
9. The worlds premier cardiovascular congress goes to Amsterdam
10. Study shows heart calcium scan predictive of diabetes-related death from cardiovascular disease
11. High hormone levels put young black males at risk for cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a jump ... winner will earn a $1,000 scholarship and have his or her video posted on ... deadline is May 31, with the winner announced on June 9. , The competition ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this week ... Tranquility privacy panel system was designed to deliver the ideal blend of acoustic ... and provide the visual privacy required to maintain concentration levels and increase productivity. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Allegheny Health Network ... patients who seek access to the Network’s programs and services in the greater Pittsburgh ... specialty care appointments will be offered one for that same afternoon. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, a ... throughout eastern Georgia, is embarking on a charity effort to raise awareness and ... Americans every year than anything else, yet risk factors associated with heart disease ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the ... in Germany , has purchased a ... University Clinic Heidelberg as part of its initiative for ... will be headed by Medical Director and Professor Jürgen ... the German Cancer Research Center (DKFZ), the Heidelberg Heavy ...
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
Breaking Medicine Technology: